Reviewing Consistency and Adequacy of Public vs. Commercial Health Insurance for American Children
JAMA study evaluates differences in coverage types and potential from 2016-2021.
GSK Survey Discovers Extensive Misconceptions About Shingles
Findings show that a considerable number of adults remain uneducated on how herpes zoster is triggered.
Phase 3 Trial for GSK’s Blenrep Yields Positive Results in Relapsed or Refractory Multiple Myeloma
Blenrep significantly extended the time to disease progression or death against existing care methods as a second-line treatment for relapsed or refractory multiple myeloma.
Research Explores Adverse Outcomes From Energy Drink Intake Before, During Pregnancy
JAMA study investigates whether consuming energy drinks was associated with adverse pregnancy outcomes and whether caffeine consumption affects fetal-growth restriction.
Citing Ongoing Drug Shortages, Biden Administration Invokes Defense Production Act
Law aims to mitigate ongoing global drug shortages.
Phase 3 Clinical Trial for Dupixent Reports Significant Reduced COPD Exacerbations
Trial results expected to accelerate the potential of Dupixent to become the first FDA-approved treatment for chronic obstructive pulmonary disease.
Investigating Industry Involvement in Modern Clinical Trials
Study aims to find ways industry gets involved in the most influential clinical trials, and how transparent these trials are.
Phase 3 Study for AbbVie’s Ubrelvy Reports Promising Results
Medication focuses on the acute treatment of migraines.
The Importance of the Medical Affairs Function in Pharmaceutical Companies
Study emphasizes role in bridging research and development and commercial/marketing functions.
Analyzing Risks of Online Marketing for Teeth Whitening Products, Post-COVID
Heliyon study evaluates online information, labeling accuracy, and quantitative analysis of high peroxide content gels.
Highlighting the Need for More Data to Achieve Global Health Equity
JAMA study argues that addressing social determinants of health is crucial to narrowing life expectancy gaps between high- and low-income countries.
The Promise and Concerns With AI in Pharma Research and Development
The global cost of clinical research and trials is estimated to exceed $85 billion by 2030, which provides an opportunity for artificial intelligence to streamline processes.
Experts: It Will Take More Than Government Regulation of Pharmacy Benefit Managers to Lower Drug Costs
Proposed legislation aims to address pharmacy benefit manager tactics to reduce prescription drug prices.
Medical Debts in America: Collections, Aggressive Tactics, and Consequences
The growing issue of medical debt has caused stakeholders to reevaluate tactics as the cost of pharmaceutical healthcare continues to rise.
Abbott’s Food as Medicine Program Reports Clinical Improvements in Patients with Diabetes
Healthy Food Rx provides home-delivered medical prescriptions of healthy food to help address diabetes.
Psychedelic Medicine: Developments, Evaluations, and Political Enthusiasm
A look into the potential effect of psychedelic drugs on various illnesses, such as mental health conditions.
Janssen Sends Data for Phase III Children’s Pulmonary Tuberculosis Treatment to FDA and EMA
Company aims to receive approval on a Type II Variation application for Sirturo for patients with pulmonary tuberculosis.
Congress Launches Investigation into FDA Drug Shortage Response
House Committee on Oversight and Accountability request documents on agency’s drug shortage mitigation strategies.
Medicare Price Negotiations: Will Big Pharma’s Opposition Push Back Future Drug Releases?
Inflation Reduction Act expected to reduce maximum achievable revenues for many top selling products.
ADHD Drug Shortages: Causes, Implications, and Solutions
Due to a global demand, treatments such as Adderall and Ritalin have been in short supply for the management of attention-deficit hyperactivity disorder.
The Impact of GLP-1 Weight Loss Drugs on Patients, Healthcare Business
The rise in popularity of GLP-1 weight-loss drugs, such as Ozempic, Wegovy, and Mounjaro, has had a wide-reaching impact across the healthcare industry and beyond.
Lexicon Pharmaceuticals’ Heart Failure Treatment Added to Express Scripts Formulary
Inpefa to be added on pharmacy benefit manager’s basic and high-performance formularies for commercially insured patients.
FDA Grants Fast Track Designation to Sellas Life Sciences’ SLS009 for Lymphoma
SLS009 is a novel CDK9 inhibitor under investigation for the treatment of relapsed/refractory peripheral T-cell lymphomas.
Arrivent’s Furmonertinib Receives FDA Breakthrough Therapy Designation
Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
2 Commerce Drive Cranbury, NJ 08512